How do the judges select the Scrip Awards winners?
Scrip Awards 2018 judges:
The Scrip Awards prides itself on its Judging Panel, which is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.
The 17 judges separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience, ensuring a considered response to every individual submission. Each category is reviewed by at least three judges who do not confer.
The judges mark each entry against the published criteria for its category, and the scores and rankings are then collated by the Scrip Awards team to determine which entries are included in the shortlist, and the ultimate winner.
The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges' decision is final and neither the organizers nor the Judging Panel will enter into any correspondence about the results. Judging will take place throughout July, and the shortlist will be announced in early September.
Details of the winners are strictly embargoed until the night but further details of all of the shortlisted entries will be published in Scrip in the weeks leading up to the ceremony on November 28.
Director, LB Training and Development
Brown is an independent pharmaceutical project management, QA and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 20 years of experience of managing clinical development projects, and training in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and LB Training and Development. She is also co-author of several books including, Project Management for the Pharmaceutical Industry.
CEO, C4X Discovery
Dix is one of the UK's leading pharma and biotech entrepreneurs. He has more than 25 years' experience life sciences, with over 20 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology.
Dix is currently CEO of C4X Discovery and Chairman of Centauri Therapeutics and Touchlight, and is also a non-executive director of the Medicines Discovery Catapult and Carrick Therapeutics. Dix was formerly co-founder and chief executive of Convergence Pharmaceuticals, a pain-specialist pharmaceuticals company acquired by Biogen Idec in 2015. Previously he had been a founder and CEO of PowderMed, and chair of Auralis. Before that Dix was held R&D roles at PowderJect Pharmaceuticals until its acquisition by Chiron Vaccines in 2003, and GlaxoWellcome
Laurie A. Halloran
President & CEO, Halloran Consulting Group, Inc.
Laurie founded Halloran Consulting Group in 1998 and has grown the business from a start-up to a highly regarded national consultancy with over 150 clients. These clients range from pre-funded startups who require regulatory and organizational growth strategies to global life science companies who need expertise managing product development challenges. She is able to draw additional expertise from her team in identifying and solving questions around strategy, regulatory, quality, organizational efficiency, complaint handling, human factors, manufacturing, medical affairs and compliance issues.
Earlier in her career, Halloran worked in the outsourcing services realm during PAREXEL International's rapid growth phase. She later led clinical development at OXiGENE and Antigenics. Her advisory Board positions include Boston University's School of Public Health, Leslie University Alumni Advisory Board, and Merck/EMD Serono's Precision Medicine. She also serves on the New England Women in Science Executive's Board of Directors.
Halloran has taught at George Washington University and Harvard University, and currently lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program.
Independent Adviser, Consultancy
Hargreaves is an independent adviser for private equity. His career in healthcare spans academia, pharma, venture capital and private equity.
Following his early career as a lecturer in pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle which included the commercialisation of the blockbuster Nexium. In 1997, he moved to 3i plc in the innovative growth period of biotech venture capital. More recently he originated several significant growth capital deals and buyouts.
Hargreaves currently advises selected private equity firms and spends a proportion of his time in the charity sector.
Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec CEO in November 2017, Jenkins served as president and CEO of Dimension Therapeutics,a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years-including serving as senior vice president and head of global medical affairs. Earlier in her career, Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc.(Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. FDA, and serves on the board of the Center for Talent Innovation in the U.K.
Trevor M Jones CBE
Chairman, Simbec-Orion Group
Jones is chair of Simbec-Orion Group and Director Arix Bioscience plc. He was formerly R&D director of The Wellcome Foundation, a director of Allergan Inc. and director general of the Association of the British Pharmaceutical Industry (ABPI). He is a visiting professor at King’s College, London.
Founder, Mehta Partners
Mehta founded and is managing member of Mehta Partners, LLC. His analytical insights on global healthcare have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California and UCLA, he has worked with senior biopharma leaders and investment managers for over 30 years.
Mehta’s career began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly, now known as Mehta Partners.
Gather Health is Mehta ‘s new initiative to empower patients while enhancing physician productivity. Gather Health brings together healthcare providers and patients’ social networks, enabling patients to get real-time and active resources and motivation to improve outcomes.
Chairman, Institute of Clinical Research, Director ALM Consultancy
Since 2012, Messom has been chairman of the Institute of Clinical Research; the oldest independent membership-led professional body for global clinical researchers. With a background in molecular genetics, Messom has almost 20 years’ industry experience working both within pharmaceutical companies and clinical research organisations.
Messom has detailed experience of directing global clinical trials and has worked in a wide variety of leadership roles, within pharma companies and CROs not only for project and monitoring teams, but also data management, outsourcing, informatics and translational medicine departments. Most recently she has provided consultancy support to an academic group working on a translational medicine project and operational consultancy to a mid-sized pharma company working in Phase III and IV.
Chairman, Strategic Business Partners
Phacharintanakul is chair of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chair of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.
President, Center for Medicine in the Public Interest
Pitts is president of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Pitts was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised the FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee consultant to the FDA’s Risk Communications Advisory Committee.
His specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, DTC/ItP, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, and nutritional labeling.
Raymond F. Schinazi
Frances Winship Walters Professor of Pediatrics and Director , Laboratory of Biochemical Pharmacology at Emory University
Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co-Director of the HIV Cure Scientific Working Group for the NIH-sponsored Emory University Center for AIDS Research. Schinazi has authored over 500 peer-reviewed papers and seven books and holds over 100 issued US patents, which have resulted in 15 NDAs.
A world leader in nucleoside chemistry, Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs stavudine, lamivudine, emtricitabine, telbivudine, and most recently sofosbuvir. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented.
After 35 years of service, Schinazi retired from the Department of Veterans Affairs with his latest position as senior research career scientist. Schinazi was appointed to the Global Virus Network executive committee in 2016.
Director-Analyst, Edison Investment Research
Smith began his career as a scientist in the R&D division of ICI and then SmithKline Beecham. After completing his PhD in molecular biology at the University of Nottingham and Glaxo, and then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban. In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for four life science specific funds – 3i Bioscience Investment Trust, International Biotechnology Trust, and AXA Framlington Biotech Fund.
After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.
In 2017 Smith moved to the pricing & market access group at ICON in London where he advised big pharma and smaller life science companies on the valuation and commercialisation of their products and returned to the City at the end of 2017 to work at Edison.
Founder, Spiegel Consulting
Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. Spiegel is a fellow of the American College of Physicians and has received numerous awards and fellowships. He serves as an advisor to Warburg Pincus and the Israeli Biotech Fund and on the boards of numerous biotechnology companies and non-profit organizations. He is an assistant professor Weill Cornell Medical School and associate fellow in the University of Pennsylvania Center for Bioethics.
Chairman, Chesyl Pharma
Stahel worked for Wellcome Plc (now GlaxoSmithKline PLC) from 1967 to 1994, in Switzerland, Italy, Thailand, Singapore and the UK. He joined Shire Pharmaceuticals Group as chief executive officer in March 1994 and during his tenure implemented six mergers and acquisitions which in less than a decade transformed the private $30m company with $3m sales and 50 employees into a FTSE 100 company with a market capitalisation of about $3.2bn, revenues of $1.1bn and 1,800 employees. Since leaving Shire in 2003, he has been chairman and mentor for a series of biotech companies, including Jazz Pharmaceuticals (EUSA Pharma USA) Inc., Cosmo Pharmaceuticals NV, PowderMed Ltd., Midatech, Chesyl Pharma, Ergomed, Connexios Life Sciences, Norwood Immunology and Newron Pharmaceuticals.
Chair | Editor, Hale & Tempest Co Ltd | Journal of Generic Medicines
Tempest has worked in the pharmaceutical industry for the last 46 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 he held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Previously, Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as Chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net-worth individuals on their strategy in Asia. Tempest is a non-executive director of SRL Diagnostics, Fortis Healthcare, Touch Digital Media, Religare Capital Markets and Glenmark Pharmaceuticals. Currently he is Editor of theJournal of Generic Medicinesand a non-executive director of the United Nations Medicines Patent Pool.
Independent Consultant and Writer, SciTechStrategy
Thong consults on business strategy and collaborations in the bioscience sector, and writes a regular blog on these topics, SciTechStrategy. Thong’s full-length book,Biopharma R&D Partnerships: From David & Goliath to Networked R&D, was published in January 2016, derived from the practical experiences of over forty different organisations. He has previously been co-head of the Cap Gemini Life Sciences Group, managing director of Datamonitor’s healthcare division, a non-executive board member of the listed US mid-sized pharmaceutical company Alpharma, and a co-founder of two specialist consultancies focusing respectively on mid-sized biopharma companies and change management for scientific organisations.
Sir Gregory Winter
Master, Trinity College Cambridge
Winter is the Master of Trinity College, Cambridge and a Fellow of the Royal Society and until recently a member of the Medical Research Council's Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur and best known for his research and inventions relating to therapeutic antibodies made at the LMB.
He has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GlaxoSmithKline) and Bicycle Therapeutics in 2009.